Innovotech Secures $234K from NRC IRAP for Antimicrobial Testing

Innovotech Inc., a leading life sciences services company, has secured up to $234,000 CAD in advisory services and research funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The funding will support its subsidiary Innovotech Labs Corporation in developing new antimicrobial testing services for medical devices such as catheters, implants, and wound dressings. This initiative aligns with evolving international regulatory standards and addresses manufacturers' needs for testing that better reflects real-world use, particularly in areas like biofilm formation and microorganism translocation. By advancing these capabilities, Innovotech aims to enhance its service offerings, bolster regulatory readiness, and help clients demonstrate device safety and performance more effectively. Craig Milne, CEO of Innovotech, emphasized that the NRC IRAP support will deepen their technical expertise, solve customer challenges, and reduce infections for better health outcomes. The company, known for its MBEC Assay® platform and ISO-certified laboratories, serves medical device, pharmaceutical, and industrial sectors, with a strong focus on biofilm science and antimicrobial testing. This development positions Innovotech to meet rising demand for higher-complexity testing as standards evolve. For more details, visit the original release on www.newmediawire.com.

Innovotech's stock is listed on the TSX Venture Exchange under the symbol IOT and on the OTCQB under IOTCF. The company's subsidiary, Innovotech Labs Corporation, will utilize the NRC IRAP funding to build upon foundational development from last year, creating more robust and fit-for-purpose testing methods. This aligns with the increasing demand from medical device manufacturers for advanced testing that provides clearer decision-making data. The funding will help Innovotech expand its service offerings, support regulatory readiness, and aid customers in demonstrating device safety and performance more effectively. The company's focus on biofilm science and antimicrobial testing is critical as healthcare-associated infections remain a significant concern. By improving testing for medical devices, Innovotech contributes to reducing infection rates and improving patient outcomes. The company's expertise, combined with this new funding, underscores its role as a key player in the life sciences sector.